Mahlakõiv, Tanel, juhendajaTeesalu, Tambet, juhendajaShahpazir, AnaTartu Ülikool. Loodus- ja täppisteaduste valdkondTartu Ülikool. Tehnoloogiainstituut2025-07-102025-07-102025https://hdl.handle.net/10062/112111Chimeric antigen receptor (CAR)-T cell therapies have demonstrated remarkable success in B-cell malignancies but have yet to show comparable outcomes in solid tumors. A major obstacle is the scarcity of tumor-specific antigens that enable precise and effective targeting. Claudin 6 (CLDN6), an oncofetal tight junction protein, serves as a promising target due to its aberrant upregulation in several solid tumors and absence in healthy adult tissues. In this study, we identified two CLDN6-specific antibodies and leveraged them to generate two second-generation CAR-T cells. Both constructs selectively eliminated CLDN6-positive tumor cells in vitro, while exhibiting distinct profiles in terms of efficacy and specificity. These findings present a promising avenue for developing next-generation immunotherapies for CLDN6-expressing solid tumors and provide a foundation for further development of CAR-T therapy in the treatment of solid tumors.enAttribution-NonCommercial-NoDerivs 3.0 Estoniahttp://creativecommons.org/licenses/by-nc-nd/3.0/ee/Cancer immunotherapyCAR-T cell therapysolid tumorCLDN6magistritöödThesis